Media

Follow our progress and stay up to date with our press releases and media coverage.

Press Releases

GeneVentiv Invited to Present at BioPharm America 2023

GeneVentiv Invited to Present at BioPharm America 2023

August 30, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced it has been invited to present at BioPharm AmericaTM, which will be held in Raleigh,...

read more
GeneVentiv Welcomes New Advisors

GeneVentiv Welcomes New Advisors

August 29, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that it has added Robert Baffi and Deborah Wild as Advisors as the Company prepares...

read more
GeneVentiv to Attend BIO International 2023

GeneVentiv to Attend BIO International 2023

May 3, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO International 2023, which will be held in Boston, MA from June 5-8, 2023. ...

read more
GeneVentiv Expands Management Team and Board of Directors

GeneVentiv Expands Management Team and Board of Directors

January 23, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that it has expanded the Company’s management team and board of directors with the...

read more

In the News

Universal hope for hemophilia

Universal hope for hemophilia

Universal hope for hemophilia Current hemophilia treatments have limitations for a significant number of patients. That’s why UNC-connected startup GeneVentiv Therapeutics is developing the first universal, single-dose gene therapy for all types of hemophilia,...

read more
Potential Gene Therapy GENV-HEM Earns Orphan Drug Status

Potential Gene Therapy GENV-HEM Earns Orphan Drug Status

Hemophilia News Today by Marta Figueiredo PhD | November 3, 2021 The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GENV-HEM, GeneVentiv Therapeutics’ investigational gene therapy for hemophilia A and B patients, with or without...

read more
UNC Gene Therapy Spinoff Aims to Cure Hemophilia

UNC Gene Therapy Spinoff Aims to Cure Hemophilia

Latest spinoff from UNC’s Gene Therapy Center wants to find a cure for hemophilia Read more here: https://www.newsobserver.com/news/business/article247379109.html#storylink=cpy RALEIGH UNC-Chapel Hill’s gene therapy center has birthed yet another startup in the...

read more